Skip to main content
Clinical Trials/ISRCTN33957677
ISRCTN33957677
Completed
N/A

A pilot study to examine the safety and efficacy of posterior juxta-scleral (80 mg) triamcinolone acetonide, administration, in addition to Visudyne (verteporfin) photodynamic therapy for predominantly classic choroidal neovascularisation secondary to age-related macular degeneration: an open-label, randomised, active controlled trial

King's College Hospital (UK)0 sites80 target enrollmentJanuary 18, 2008

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
King's College Hospital (UK)
Enrollment
80
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 18, 2008
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
King's College Hospital (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Age 50 years or older, male and female
  • 2\. Clinical diagnosis of age\-related macular degeneration (AMD)
  • 3\. Subfoveal choroidal neovascularisation (CNV) confirmed by fluorescein angiography
  • 4\. Best corrected visual acuity of 35 letters on Early Treatment Diabetic Retinopathy Study (ETDRS) chart

Exclusion Criteria

  • 1\. Inability to understand or sign consent form
  • 2\. The patient has a current medical condition or history of a medical condition that would be likely to preclude scheduled study visits
  • 3\. Patient has a current ophthalmic condition or history of an ophthalmic condition that might compromise the assessment of the treatment
  • 4\. Signs of a myopic retina or refraction of greater than \-8 dioptres in their current or previous glasses prescription
  • 5\. Signs of other retinal conditions that may have caused the CNV such as angioid streaks, choroidal rupture, and old chorio\-retinitis
  • 6\. Open angle glaucoma
  • 7\. At increased risk of developing glaucoma such as having; pigment dispersion syndrome or pseudoexfoliation
  • 8\. Unable to have a good quality fluorescein angiogram taken, e.g., due to head tremor or media opacity

Outcomes

Primary Outcomes

Not specified

Similar Trials